Shares of Global Blood Therapeutics (GBT)
are trading 42% higher at a price of $48.17 at the time of this writing.
The stock is trading higher on rumors of a potential buyout. The news mentioned in a Bloomberg article
that was light on specifics, as sources requested anonymity. The news is several days old, but the price continues to move at the time of this writing.
Global Blood Therapeutics has been trading between a 52-week high of $48.49 and a 52-week low of $21.65. The stock has a market cap of $3.14 Billion.
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD.